The page describes an approach to dry eye analysis that distinguishes aqueous tear deficiency (ATD), a tear quantity problem, from meibomian gland dysfunction (MGD), a tear quality problem.
First the good: “Global health care company Grifols has announced that the US Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application to initiate a phase 2 trial to assess its immunoglobulin (IG) drops (GRF312 ophthalmic solution) for the treatment
https://glance.eyesoneyecare.com/stories/2026-04-07/fda-issues-nationwide-voluntary-recall-for-over-3m-eye-drop-bottles/ If it sounds like Groundhog Day when I say that more over the counter artificial tear products are being recalled due to possible germ contamination , then I guess it is. Sadly
Dr. Jaccoma specializes in laser and cataract surgery, dry eye and aesthetic eye care, and vision restoration. He is board certified in ophthalmology and belongs to several medical organizations.
Dry eye disease involves too few tears or an imbalance in tear composition, which can impair the nourishment, lubrication and protection of the eye’s surface. Symptoms range from irritation and occasional blurring to burning, tearing, redness, scratchiness, glare and surface damage.
